Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive worldwide, sublicensable JADE301 license expands Jade’s pipeline across all therapeutic areas.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive worldwide, sublicensable JADE301 license expands Jade’s pipeline across all therapeutic areas
- Up to $22.0M in development and regulatory milestones, including $2.5M upon first Phase 1 patient dosing
- Additional sublicensing milestones up to approximately $20.1M per product
- Future royalties: low-to-mid-single digits for monospecific products and mid-single digits for multispecific products
- Paragon barred from new Target antibody campaigns in the Field for at least five years, supporting competitive exclusivity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.